Proteon logo     Print Page | Close Window

SEC Filings

8-K
PROTEON THERAPEUTICS INC filed this Form 8-K on 11/07/2017
Entire Document
 

Introductory Comment 

Throughout this Current Report on Form 8-K, the terms “we,” “us,” “our”, “Company” and “Proteon” refer to Proteon Therapeutics, Inc.

Item 2.02. Results of Operations and Financial Condition.

On November 7, 2017, the Company issued a press release announcing its financial results for the third quarter ended September 30, 2017. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information in this Current Report on Form 8-K under Items 2.02, including the exhibit attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.   Description
     
99.1   Press Release, dated November 7, 2017, issued by Proteon Therapeutics, Inc. announcing its Third Quarter 2017 Financial Results